Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

摘要: AbstractBackground. Patients with chemotherapy refractory metastatic colorectal cancer and KRAS mutations have no effective treatment option. The present study evaluated the efficacy of temsirolimus in mCRC mutations. Furthermore, we wanted to investigate if resistance could be reversed by addition irinotecan. Finally, analyzed pre-treatment blood samples for association between quantitative measures mutated alleles clinical outcome. Material methods. received weekly 25 mg until progression. Thereafter patients were treated combination therapy comprising biweekly irinotecan 180 mg/m2 temsirolimus. A polymerase chain reaction method was used quantify plasma (pKRAS). Results. Sixty-four included. Treatment well tolerated. Thirty-eight percent achieved stable disease on monotherapy 63% therapy. F...